Provisions of RV1 vaccine alone or diarrhoea management alone are both less cost effectiveness alternatives.
An extension of current endoscopic screening to include patients with gastro-oesophageal reflux disease would have even less cost effectiveness, even though this group is at increased risk of developing oesophageal cancer (Iftikhar et al, 1992).
Compared to smoking – a comparatively "old" challenge – it is not surprising that thus far significantly less (cost- effectiveness evidencost- effectivenessatevidencerms of thasprevention of dietary intake and obeenty.
When this latter proportion is about 20.3%, the prophylaxis strategy is a less cost effective strategy (the incremental cost-effectiveness ratio of prophylaxis vs. screening is around 1500 $/LYG).
Based on the data used in the model, cementless prostheses appear to be less costly than cemented ones over 5 years, but not less cost-effective when an incremental cost effectiveness ratio of less than €50,0000 per QALY was adopted.
However, if, on the other hand, unreported deaths more often occur in adults, the inclusion of this underreporting in mortality could lead to less favourable cost-effectiveness Furthermore, we did not take side effects of the booster vaccine into account.
While there were increased health benefits for females when boys were included at any coverage level, the marginal impact on cervical cancer incidence diminished as coverage in girls increased, while total costs nearly doubled (assuming same coverage for both genders), resulting in less attractive cost-effectiveness ratios.
When we add the health care costs of unrelated disease in added years of life into our evaluation of the fruit and vegetable interventions (results not shown), we get even less favourable cost-effectiveness ratios.
Screening persons aged under 50 years old yielded less favourable cost-effectiveness ratios than commencing screening at age 50 years.
Dhainaut and colleagues [ 64], applying Pscore matching, also observed less favorable cost-effectiveness ratios; the authors reported a cost per QALY of €34,000 in routine clinical practice in France.
